Synch advises AlzeCure Pharma on SEK 30.1 million rights issue oversubscribed to 329 percent

"Synch acted as legal advisor to AlzeCure Pharma AB on a SEK 30.1 million rights issue that was oversubscribed to approximately 329%. The financing will support acceleration of pain programmes and continued development of Alzheimer's projects, building on recent collaborations with Eli Lilly and QuantumCell ApS."

Synch acted as legal advisor to AlzeCure Pharma AB in connection with its recently completed SEK 30.1 million rights issue. The rights issue was heavily oversubscribed to approximately 329 percent. AlzeCure is a pharmaceutical company developing innovative drug candidates for diseases affecting the nervous system, including Alzheimer’s disease and pain. The new financing enables AlzeCure to accelerate the development of its pain projects while continuing to advance its Alzheimer’s disease programmes together with partners. AlzeCure has recently entered into a collaboration and out-licensing agreement with Eli Lilly regarding the global rights to the Alzheimer’s project Alzstatin ACD680, with a total deal value, excluding royalty payments, that may exceed $1 billion USD. The company has also entered into an out-licensing and collaboration agreement with QuantumCell ApS regarding the global rights to AlzeCure’s Alzheimer’s platform NeuroRestore, including the leading drug candidate ACD856. Synch represented AlzeCure Pharma AB with a team composed by: the Capital Markets team consisting of Mattias Anjou, Sofia Tångelin and Clara Löfgren.

Menu

Synch advises AlzeCure Pharma on SEK 30.1 million rights issue oversubscribed to 329 percent

Read the full story

Menu

Synch advises AlzeCure Pharma on SEK 30.1 million rights issue oversubscribed to 329 percent

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads